| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Follicular | 43 | 2024 | 460 | 8.890 |
Why?
|
| Lymphoma, Non-Hodgkin | 46 | 2019 | 1376 | 2.740 |
Why?
|
| Bone Marrow Transplantation | 63 | 2011 | 2709 | 2.350 |
Why?
|
| B-Lymphocytes | 58 | 2021 | 4794 | 1.660 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 48 | 2023 | 11886 | 1.600 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 23 | 2021 | 1642 | 1.570 |
Why?
|
| Lymphoma, B-Cell | 18 | 2018 | 945 | 1.320 |
Why?
|
| Transplantation, Autologous | 52 | 2023 | 2126 | 1.190 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 16 | 2014 | 696 | 1.170 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 7 | 2024 | 892 | 1.140 |
Why?
|
| Antibodies, Monoclonal | 48 | 2023 | 9264 | 1.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 12 | 2023 | 1437 | 0.950 |
Why?
|
| Stem Cell Transplantation | 11 | 2023 | 1602 | 0.890 |
Why?
|
| Cancer Vaccines | 5 | 2024 | 1043 | 0.880 |
Why?
|
| Cyclophosphamide | 28 | 2014 | 2227 | 0.880 |
Why?
|
| Vidarabine | 5 | 2015 | 337 | 0.860 |
Why?
|
| Bone Marrow Purging | 17 | 2007 | 108 | 0.850 |
Why?
|
| Lymphoma | 15 | 2017 | 1900 | 0.830 |
Why?
|
| Lymphoma, Mantle-Cell | 5 | 2020 | 240 | 0.800 |
Why?
|
| Hodgkin Disease | 10 | 2019 | 1384 | 0.770 |
Why?
|
| Antineoplastic Agents | 19 | 2023 | 13698 | 0.730 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 3 | 2014 | 125 | 0.700 |
Why?
|
| Integrins | 7 | 2004 | 843 | 0.660 |
Why?
|
| Whole-Body Irradiation | 17 | 2007 | 435 | 0.650 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 17 | 2023 | 5716 | 0.650 |
Why?
|
| Combined Modality Therapy | 32 | 2016 | 8559 | 0.600 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2016 | 230 | 0.580 |
Why?
|
| Antigens, CD20 | 7 | 2011 | 199 | 0.540 |
Why?
|
| Lymphocyte Activation | 28 | 1997 | 5505 | 0.490 |
Why?
|
| Lymphocyte Depletion | 11 | 2003 | 605 | 0.470 |
Why?
|
| Protein-Tyrosine Kinases | 7 | 2008 | 2433 | 0.450 |
Why?
|
| Chromosomes, Human, Pair 14 | 9 | 2014 | 286 | 0.440 |
Why?
|
| Remission Induction | 18 | 2016 | 2408 | 0.440 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 12 | 2002 | 318 | 0.440 |
Why?
|
| Immunoglobulin Idiotypes | 2 | 2014 | 201 | 0.440 |
Why?
|
| Vaccination | 2 | 2024 | 3438 | 0.430 |
Why?
|
| Vincristine | 12 | 2014 | 1040 | 0.430 |
Why?
|
| Disease-Free Survival | 20 | 2019 | 6856 | 0.430 |
Why?
|
| Chromosomes, Human, Pair 18 | 8 | 2014 | 247 | 0.430 |
Why?
|
| DNA Copy Number Variations | 2 | 2012 | 2055 | 0.420 |
Why?
|
| Antigens, CD | 23 | 2014 | 4032 | 0.420 |
Why?
|
| Transplantation Conditioning | 8 | 2012 | 1601 | 0.420 |
Why?
|
| Neoplasm Proteins | 6 | 2021 | 3608 | 0.410 |
Why?
|
| Accreditation | 1 | 2015 | 477 | 0.400 |
Why?
|
| Leukemia | 11 | 2016 | 1520 | 0.400 |
Why?
|
| Phosphoproteins | 6 | 1997 | 2452 | 0.390 |
Why?
|
| Lymphoproliferative Disorders | 4 | 2012 | 529 | 0.380 |
Why?
|
| Recurrence | 19 | 2015 | 8513 | 0.380 |
Why?
|
| Prednisone | 12 | 2014 | 1567 | 0.370 |
Why?
|
| Genes, myc | 1 | 2012 | 391 | 0.360 |
Why?
|
| Immunophenotyping | 12 | 2014 | 1866 | 0.360 |
Why?
|
| Receptors, Antigen, B-Cell | 5 | 1997 | 547 | 0.360 |
Why?
|
| Watchful Waiting | 1 | 2015 | 498 | 0.360 |
Why?
|
| Doxorubicin | 14 | 2012 | 2234 | 0.360 |
Why?
|
| Disease Management | 3 | 2018 | 2537 | 0.350 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 829 | 0.350 |
Why?
|
| Humans | 210 | 2024 | 768970 | 0.340 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2005 | 618 | 0.340 |
Why?
|
| Translocation, Genetic | 12 | 2014 | 1395 | 0.340 |
Why?
|
| Menisci, Tibial | 1 | 2012 | 267 | 0.340 |
Why?
|
| Inheritance Patterns | 1 | 2012 | 344 | 0.330 |
Why?
|
| Antigens, Surface | 12 | 1996 | 1616 | 0.330 |
Why?
|
| Treatment Outcome | 40 | 2024 | 65480 | 0.320 |
Why?
|
| Neoplasms, Second Primary | 4 | 2017 | 1060 | 0.320 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2013 | 957 | 0.320 |
Why?
|
| Dendritic Cells, Follicular | 3 | 2011 | 50 | 0.320 |
Why?
|
| Tyrosine | 5 | 1997 | 1427 | 0.310 |
Why?
|
| Proteins | 7 | 2009 | 6011 | 0.310 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2009 | 199 | 0.300 |
Why?
|
| Middle Aged | 90 | 2024 | 223737 | 0.300 |
Why?
|
| Receptors, Very Late Antigen | 3 | 1993 | 74 | 0.300 |
Why?
|
| Immunologic Factors | 2 | 2008 | 1597 | 0.290 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2009 | 706 | 0.280 |
Why?
|
| Disease Progression | 14 | 2015 | 13674 | 0.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2008 | 4356 | 0.270 |
Why?
|
| Male | 94 | 2024 | 365203 | 0.270 |
Why?
|
| Adult | 91 | 2024 | 223851 | 0.270 |
Why?
|
| Cell Adhesion | 10 | 2002 | 3102 | 0.260 |
Why?
|
| Tibia | 1 | 2012 | 1076 | 0.260 |
Why?
|
| Quinazolinones | 2 | 2019 | 219 | 0.260 |
Why?
|
| Cell Adhesion Molecules | 8 | 1996 | 1614 | 0.260 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2008 | 249 | 0.260 |
Why?
|
| Prognosis | 24 | 2018 | 30046 | 0.250 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2012 | 3810 | 0.250 |
Why?
|
| Antigens, Neoplasm | 13 | 2018 | 2001 | 0.250 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 588 | 0.250 |
Why?
|
| Genetic Markers | 1 | 2012 | 2604 | 0.250 |
Why?
|
| Phosphotyrosine | 2 | 1997 | 458 | 0.250 |
Why?
|
| Genes, bcl-2 | 3 | 2014 | 119 | 0.250 |
Why?
|
| Neoplasm Staging | 7 | 2015 | 11262 | 0.250 |
Why?
|
| Aged | 49 | 2024 | 171786 | 0.250 |
Why?
|
| Female | 101 | 2024 | 397515 | 0.250 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 9 | 2001 | 896 | 0.250 |
Why?
|
| Palatine Tonsil | 8 | 2004 | 193 | 0.240 |
Why?
|
| Cell Separation | 9 | 2003 | 1728 | 0.240 |
Why?
|
| Survival Rate | 18 | 2017 | 12873 | 0.240 |
Why?
|
| Hematopoietic Stem Cells | 10 | 2006 | 3408 | 0.230 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2012 | 2884 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 11 | 2017 | 4528 | 0.230 |
Why?
|
| Chemokine CCL2 | 2 | 2009 | 606 | 0.230 |
Why?
|
| Purines | 2 | 2019 | 615 | 0.230 |
Why?
|
| Chromosome Aberrations | 5 | 2015 | 1780 | 0.230 |
Why?
|
| Epididymis | 1 | 2005 | 227 | 0.220 |
Why?
|
| Survival Analysis | 17 | 2019 | 10115 | 0.220 |
Why?
|
| Gene Expression Profiling | 8 | 2021 | 9549 | 0.220 |
Why?
|
| Germ-Line Mutation | 1 | 2012 | 1887 | 0.210 |
Why?
|
| Transplantation, Homologous | 16 | 2011 | 4835 | 0.210 |
Why?
|
| K562 Cells | 2 | 2024 | 648 | 0.210 |
Why?
|
| Salvage Therapy | 7 | 2019 | 1277 | 0.210 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2017 | 1399 | 0.210 |
Why?
|
| Genes, Immunoglobulin | 2 | 2014 | 286 | 0.200 |
Why?
|
| Interferon-beta | 1 | 2004 | 349 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2023 | 9442 | 0.200 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2002 | 660 | 0.200 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2003 | 263 | 0.200 |
Why?
|
| T-Lymphocytes | 18 | 2014 | 10276 | 0.190 |
Why?
|
| Graft vs Host Disease | 13 | 2011 | 3048 | 0.190 |
Why?
|
| Cytarabine | 5 | 2020 | 697 | 0.190 |
Why?
|
| Signal Transduction | 9 | 2004 | 23653 | 0.190 |
Why?
|
| Radioimmunotherapy | 2 | 2016 | 93 | 0.190 |
Why?
|
| Ricin | 4 | 2011 | 70 | 0.190 |
Why?
|
| Receptors, Lymphocyte Homing | 3 | 1996 | 141 | 0.180 |
Why?
|
| Caspases | 1 | 2004 | 881 | 0.180 |
Why?
|
| Pyrimethamine | 1 | 2021 | 95 | 0.180 |
Why?
|
| Dendritic Cells | 6 | 1995 | 2748 | 0.180 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 4 | 2000 | 692 | 0.180 |
Why?
|
| Interferon-alpha | 2 | 2004 | 910 | 0.180 |
Why?
|
| Immunoglobulin Heavy Chains | 6 | 2016 | 648 | 0.180 |
Why?
|
| Population Surveillance | 1 | 2011 | 2597 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 9 | 2016 | 1408 | 0.180 |
Why?
|
| Lymphotoxin-alpha | 1 | 2000 | 94 | 0.170 |
Why?
|
| Interleukin-2 | 6 | 2002 | 1895 | 0.170 |
Why?
|
| Cell Communication | 8 | 2002 | 1660 | 0.170 |
Why?
|
| Follow-Up Studies | 18 | 2014 | 39394 | 0.170 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2004 | 592 | 0.170 |
Why?
|
| DNA | 3 | 2013 | 7214 | 0.170 |
Why?
|
| Lymph Nodes | 4 | 2014 | 3473 | 0.170 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 2565 | 0.170 |
Why?
|
| Immunotherapy | 5 | 2023 | 4756 | 0.170 |
Why?
|
| Receptors, Chemokine | 2 | 2002 | 652 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 13 | 2004 | 6086 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 2909 | 0.160 |
Why?
|
| Testicular Neoplasms | 1 | 2005 | 808 | 0.160 |
Why?
|
| Lymphoma, T-Cell | 1 | 2002 | 308 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 8 | 2004 | 6131 | 0.150 |
Why?
|
| Transforming Growth Factor beta | 2 | 2004 | 2004 | 0.150 |
Why?
|
| Trans-Activators | 2 | 2004 | 2858 | 0.150 |
Why?
|
| Neoplasm, Residual | 4 | 2023 | 1019 | 0.150 |
Why?
|
| Aged, 80 and over | 16 | 2021 | 59739 | 0.150 |
Why?
|
| Radiotherapy | 3 | 2017 | 1506 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2014 | 2525 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2004 | 1560 | 0.150 |
Why?
|
| Breast Implants | 1 | 2002 | 414 | 0.150 |
Why?
|
| Leukemia, Lymphoid | 3 | 1987 | 312 | 0.150 |
Why?
|
| Hematopoiesis | 6 | 2017 | 2059 | 0.140 |
Why?
|
| Antibodies, Neoplasm | 3 | 2004 | 283 | 0.140 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 1997 | 2911 | 0.140 |
Why?
|
| Antibodies, Anti-Idiotypic | 7 | 2008 | 355 | 0.140 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2010 | 2848 | 0.140 |
Why?
|
| Immunoconjugates | 2 | 2018 | 976 | 0.140 |
Why?
|
| Bone Marrow Cells | 5 | 2006 | 2414 | 0.140 |
Why?
|
| Lymphocyte Subsets | 4 | 2013 | 313 | 0.140 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 874 | 0.130 |
Why?
|
| Immunoglobulin G | 2 | 2008 | 4568 | 0.130 |
Why?
|
| Phosphorylation | 9 | 2004 | 8317 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2014 | 18068 | 0.130 |
Why?
|
| Lymphoid Tissue | 4 | 1991 | 446 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 190 | 0.130 |
Why?
|
| Tetradecanoylphorbol Acetate | 7 | 2002 | 826 | 0.130 |
Why?
|
| Cell Line | 16 | 2011 | 15604 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 10400 | 0.130 |
Why?
|
| Integrin beta Chains | 1 | 1996 | 115 | 0.130 |
Why?
|
| Antigens, Differentiation | 5 | 2000 | 921 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1997 | 631 | 0.120 |
Why?
|
| Interferon-gamma | 4 | 2009 | 3163 | 0.120 |
Why?
|
| Germinal Center | 2 | 2014 | 380 | 0.120 |
Why?
|
| Crk-Associated Substrate Protein | 4 | 1997 | 39 | 0.120 |
Why?
|
| Retinoblastoma-Like Protein p130 | 4 | 1997 | 73 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2012 | 323 | 0.110 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2014 | 105 | 0.110 |
Why?
|
| DNA-Binding Proteins | 4 | 2017 | 9618 | 0.110 |
Why?
|
| Risk Assessment | 5 | 2019 | 24333 | 0.110 |
Why?
|
| Drug Administration Schedule | 4 | 2013 | 4862 | 0.110 |
Why?
|
| Retreatment | 1 | 2015 | 600 | 0.110 |
Why?
|
| Etoposide | 2 | 2012 | 639 | 0.110 |
Why?
|
| Neutropenia | 4 | 2018 | 893 | 0.110 |
Why?
|
| Immunotoxins | 4 | 1999 | 175 | 0.110 |
Why?
|
| Spleen | 10 | 1990 | 2294 | 0.100 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2014 | 368 | 0.100 |
Why?
|
| Bone Marrow | 11 | 1994 | 2936 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2014 | 16053 | 0.100 |
Why?
|
| Secondary Prevention | 3 | 2011 | 1476 | 0.100 |
Why?
|
| Chromosome Duplication | 1 | 2012 | 79 | 0.100 |
Why?
|
| Carmustine | 1 | 2012 | 137 | 0.100 |
Why?
|
| Tumor Burden | 2 | 2015 | 1913 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2014 | 10486 | 0.100 |
Why?
|
| Cell Survival | 5 | 2004 | 5793 | 0.090 |
Why?
|
| Focal Adhesion Kinase 2 | 3 | 2002 | 87 | 0.090 |
Why?
|
| Cytoskeletal Proteins | 1 | 1997 | 1328 | 0.090 |
Why?
|
| Positron-Emission Tomography | 4 | 2012 | 6673 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2016 | 998 | 0.090 |
Why?
|
| Radiation Pneumonitis | 1 | 2011 | 100 | 0.090 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 794 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2018 | 5342 | 0.090 |
Why?
|
| Deglutition Disorders | 1 | 2017 | 641 | 0.090 |
Why?
|
| Thalidomide | 1 | 2016 | 886 | 0.090 |
Why?
|
| Cisplatin | 2 | 2009 | 1661 | 0.090 |
Why?
|
| Chemokines, CXC | 2 | 2002 | 420 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2012 | 453 | 0.090 |
Why?
|
| Antigens, CD34 | 4 | 2006 | 656 | 0.090 |
Why?
|
| Chromosome Deletion | 2 | 2012 | 1390 | 0.090 |
Why?
|
| Life Tables | 6 | 1997 | 368 | 0.090 |
Why?
|
| Age Factors | 7 | 2016 | 18435 | 0.090 |
Why?
|
| Sezary Syndrome | 1 | 2011 | 80 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2014 | 878 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 11116 | 0.080 |
Why?
|
| Immunocompetence | 1 | 2009 | 138 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2015 | 1575 | 0.080 |
Why?
|
| Nuclear Proteins | 3 | 2002 | 5804 | 0.080 |
Why?
|
| Radiation Injuries | 1 | 2017 | 1203 | 0.080 |
Why?
|
| Mycosis Fungoides | 1 | 2011 | 169 | 0.080 |
Why?
|
| Dexamethasone | 2 | 2009 | 1965 | 0.080 |
Why?
|
| Pyrroles | 1 | 2015 | 1125 | 0.080 |
Why?
|
| Genome, Human | 2 | 2012 | 4456 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 414 | 0.080 |
Why?
|
| Fibronectins | 2 | 2002 | 724 | 0.080 |
Why?
|
| Gene Expression | 5 | 2014 | 7603 | 0.080 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2008 | 69 | 0.080 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1990 | 249 | 0.080 |
Why?
|
| Histocompatibility | 2 | 2002 | 321 | 0.080 |
Why?
|
| Membrane Glycoproteins | 3 | 2010 | 3713 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 1995 | 3775 | 0.080 |
Why?
|
| Cell Division | 4 | 2005 | 4478 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 1 | 2011 | 549 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 4 | 1998 | 1356 | 0.070 |
Why?
|
| Cell Differentiation | 14 | 1998 | 11684 | 0.070 |
Why?
|
| Mesoderm | 1 | 2011 | 679 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1996 | 1966 | 0.070 |
Why?
|
| Chemokine CXCL10 | 1 | 2009 | 311 | 0.070 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 906 | 0.070 |
Why?
|
| Recombinant Proteins | 6 | 1994 | 6512 | 0.070 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 606 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 3621 | 0.070 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2009 | 180 | 0.070 |
Why?
|
| Mutation | 9 | 2016 | 30266 | 0.070 |
Why?
|
| Clinical Trials as Topic | 4 | 2008 | 8055 | 0.070 |
Why?
|
| Retrospective Studies | 14 | 2020 | 81903 | 0.070 |
Why?
|
| Lymphatic Irradiation | 2 | 2005 | 115 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 1997 | 1902 | 0.070 |
Why?
|
| Graft Survival | 7 | 2003 | 3888 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2014 | 8664 | 0.070 |
Why?
|
| Indoles | 1 | 2015 | 1836 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2017 | 3626 | 0.070 |
Why?
|
| Cytochalasin B | 2 | 1997 | 74 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2011 | 3554 | 0.070 |
Why?
|
| Sciatic Neuropathy | 1 | 2007 | 76 | 0.070 |
Why?
|
| src Homology Domains | 2 | 1997 | 361 | 0.070 |
Why?
|
| Flow Cytometry | 8 | 2004 | 5906 | 0.070 |
Why?
|
| Cell Cycle | 4 | 2005 | 2937 | 0.070 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 1616 | 0.070 |
Why?
|
| Fasciitis | 1 | 2007 | 66 | 0.070 |
Why?
|
| Incidence | 6 | 2011 | 21547 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2002 | 4592 | 0.060 |
Why?
|
| Immunotherapy, Active | 1 | 2006 | 58 | 0.060 |
Why?
|
| Complement System Proteins | 2 | 1992 | 738 | 0.060 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2021 | 658 | 0.060 |
Why?
|
| Endothelium, Vascular | 2 | 1995 | 4428 | 0.060 |
Why?
|
| Sirolimus | 2 | 2012 | 1540 | 0.060 |
Why?
|
| Time Factors | 11 | 2017 | 40261 | 0.060 |
Why?
|
| Herpesvirus 4, Human | 3 | 2009 | 1082 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 999 | 0.060 |
Why?
|
| Integrin alpha4beta1 | 2 | 1996 | 119 | 0.060 |
Why?
|
| Oligonucleotides | 1 | 2008 | 563 | 0.060 |
Why?
|
| DNA Repair | 1 | 2014 | 2054 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 1988 | 1251 | 0.060 |
Why?
|
| Blotting, Southern | 2 | 2004 | 777 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2021 | 10765 | 0.060 |
Why?
|
| Smad1 Protein | 1 | 2004 | 81 | 0.060 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2004 | 40 | 0.060 |
Why?
|
| Smad2 Protein | 1 | 2004 | 144 | 0.060 |
Why?
|
| Caspase 7 | 1 | 2004 | 50 | 0.060 |
Why?
|
| Smad Proteins | 1 | 2004 | 157 | 0.060 |
Why?
|
| Activin Receptors, Type I | 1 | 2004 | 134 | 0.060 |
Why?
|
| Activin Receptors, Type II | 1 | 2004 | 123 | 0.060 |
Why?
|
| HLA-DR Antigens | 1 | 2006 | 609 | 0.060 |
Why?
|
| Pedigree | 1 | 2012 | 4545 | 0.060 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2004 | 61 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 1151 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2010 | 2942 | 0.060 |
Why?
|
| Retinoblastoma Protein | 2 | 1997 | 673 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2008 | 1328 | 0.050 |
Why?
|
| Karyotyping | 2 | 2009 | 1177 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2002 | 225 | 0.050 |
Why?
|
| DNA, Neoplasm | 4 | 2004 | 1748 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2011 | 1739 | 0.050 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2004 | 306 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2012 | 2056 | 0.050 |
Why?
|
| Clone Cells | 3 | 2017 | 1670 | 0.050 |
Why?
|
| Biopsy | 2 | 2012 | 6805 | 0.050 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2004 | 200 | 0.050 |
Why?
|
| Mediastinum | 2 | 2017 | 272 | 0.050 |
Why?
|
| Risk | 4 | 2012 | 9621 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 2748 | 0.050 |
Why?
|
| Interleukin-4 | 6 | 2002 | 1157 | 0.050 |
Why?
|
| Gene Rearrangement | 2 | 2002 | 1148 | 0.050 |
Why?
|
| Blood Component Removal | 1 | 2003 | 132 | 0.050 |
Why?
|
| Quinones | 1 | 2002 | 78 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 1181 | 0.050 |
Why?
|
| Rifabutin | 1 | 2002 | 59 | 0.050 |
Why?
|
| Young Adult | 8 | 2013 | 60131 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 7460 | 0.050 |
Why?
|
| Polylysine | 1 | 2002 | 131 | 0.050 |
Why?
|
| Microspheres | 4 | 2002 | 789 | 0.050 |
Why?
|
| Apoptosis | 5 | 2010 | 9527 | 0.050 |
Why?
|
| Silicone Gels | 1 | 2002 | 39 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 4 | 1992 | 2474 | 0.050 |
Why?
|
| Monocytes | 1 | 1991 | 2603 | 0.050 |
Why?
|
| tRNA Methyltransferases | 1 | 2002 | 50 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2008 | 965 | 0.050 |
Why?
|
| Methotrexate | 1 | 2008 | 1723 | 0.050 |
Why?
|
| Benzoquinones | 1 | 2002 | 198 | 0.050 |
Why?
|
| Leukocytes | 1 | 1990 | 2034 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2023 | 1855 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 4 | 1997 | 1813 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 1705 | 0.050 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2002 | 306 | 0.050 |
Why?
|
| Interleukins | 4 | 1989 | 796 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2002 | 6320 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2002 | 379 | 0.040 |
Why?
|
| Receptors, CCR2 | 1 | 2001 | 216 | 0.040 |
Why?
|
| Lactams, Macrocyclic | 1 | 2002 | 319 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2009 | 1891 | 0.040 |
Why?
|
| Burkitt Lymphoma | 2 | 1993 | 338 | 0.040 |
Why?
|
| Pensions | 1 | 1979 | 16 | 0.040 |
Why?
|
| Pneumonia | 1 | 2012 | 2164 | 0.040 |
Why?
|
| Chemokine CXCL12 | 1 | 2001 | 457 | 0.040 |
Why?
|
| Cyclins | 1 | 2002 | 606 | 0.040 |
Why?
|
| Cell Death | 1 | 2005 | 1682 | 0.040 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2019 | 36 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2004 | 1337 | 0.040 |
Why?
|
| Cells, Cultured | 10 | 2002 | 19023 | 0.040 |
Why?
|
| Ubiquitin | 1 | 2004 | 843 | 0.040 |
Why?
|
| Phenotype | 11 | 2016 | 16731 | 0.040 |
Why?
|
| Cohort Studies | 5 | 2019 | 41808 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2021 | 246 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2002 | 710 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 2002 | 1990 | 0.040 |
Why?
|
| Risk Factors | 10 | 2019 | 74976 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2021 | 719 | 0.040 |
Why?
|
| RNA, Messenger | 6 | 2002 | 12806 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2004 | 1505 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2002 | 664 | 0.040 |
Why?
|
| Retirement | 1 | 1979 | 198 | 0.040 |
Why?
|
| Dentists | 1 | 1979 | 176 | 0.040 |
Why?
|
| SH2 Domain-Containing Protein Tyrosine Phosphatases | 1 | 1997 | 43 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 1997 | 114 | 0.040 |
Why?
|
| src-Family Kinases | 2 | 1997 | 539 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2001 | 1762 | 0.040 |
Why?
|
| Multiple Myeloma | 6 | 1995 | 5196 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 1997 | 121 | 0.040 |
Why?
|
| Kinetics | 2 | 2004 | 6332 | 0.040 |
Why?
|
| Eosinophils | 1 | 2002 | 953 | 0.040 |
Why?
|
| Adolescent | 15 | 2017 | 89244 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2002 | 729 | 0.030 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1999 | 414 | 0.030 |
Why?
|
| Blotting, Northern | 3 | 1999 | 1553 | 0.030 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 21188 | 0.030 |
Why?
|
| Heartburn | 1 | 2017 | 71 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2238 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2011 | 9384 | 0.030 |
Why?
|
| Prevalence | 2 | 2017 | 15879 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2000 | 1133 | 0.030 |
Why?
|
| Neoplasms | 2 | 2005 | 22389 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 1997 | 120 | 0.030 |
Why?
|
| Integrin alpha6beta1 | 1 | 1996 | 19 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2002 | 3588 | 0.030 |
Why?
|
| Receptors, Fibronectin | 1 | 1996 | 37 | 0.030 |
Why?
|
| Receptor Aggregation | 1 | 1996 | 72 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1997 | 224 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2002 | 2460 | 0.030 |
Why?
|
| Chemokines | 1 | 2000 | 963 | 0.030 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 1996 | 120 | 0.030 |
Why?
|
| Leukemia, Experimental | 1 | 2016 | 225 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 20776 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 4207 | 0.030 |
Why?
|
| Pilot Projects | 3 | 2002 | 8748 | 0.030 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 1996 | 185 | 0.030 |
Why?
|
| Massachusetts | 1 | 2008 | 8894 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 899 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2013 | 2921 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1997 | 458 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2001 | 1378 | 0.030 |
Why?
|
| Rabbits | 3 | 1997 | 4774 | 0.030 |
Why?
|
| Protein Binding | 2 | 1997 | 9344 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 354 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2017 | 352 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 1997 | 1435 | 0.030 |
Why?
|
| Boron Neutron Capture Therapy | 1 | 1994 | 51 | 0.030 |
Why?
|
| Base Sequence | 6 | 1995 | 12430 | 0.030 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2016 | 173 | 0.030 |
Why?
|
| Gliosarcoma | 1 | 1994 | 115 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 362 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 716 | 0.030 |
Why?
|
| Molecular Weight | 1 | 1996 | 2173 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2020 | 54962 | 0.030 |
Why?
|
| Molecular Sequence Data | 6 | 1997 | 17629 | 0.030 |
Why?
|
| Palliative Care | 1 | 2008 | 3644 | 0.030 |
Why?
|
| L-Selectin | 2 | 1991 | 212 | 0.030 |
Why?
|
| Lung | 1 | 2011 | 10099 | 0.030 |
Why?
|
| Midwifery | 1 | 1974 | 131 | 0.030 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 1992 | 58 | 0.030 |
Why?
|
| Cytokines | 3 | 2000 | 7453 | 0.030 |
Why?
|
| Immunologic Techniques | 1 | 1992 | 213 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 2018 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2014 | 353 | 0.020 |
Why?
|
| Neutrophils | 2 | 2003 | 3785 | 0.020 |
Why?
|
| DNA Mutational Analysis | 2 | 2017 | 4124 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 1997 | 1179 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 1839 | 0.020 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 552 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2394 | 0.020 |
Why?
|
| Tissue Donors | 2 | 2002 | 2382 | 0.020 |
Why?
|
| HLA Antigens | 3 | 1997 | 1336 | 0.020 |
Why?
|
| Ligands | 2 | 1996 | 3283 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 5864 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2011 | 233 | 0.020 |
Why?
|
| Mice | 7 | 2016 | 82072 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2012 | 252 | 0.020 |
Why?
|
| Animals | 15 | 2016 | 169335 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2012 | 4040 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1992 | 283 | 0.020 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1991 | 106 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 1996 | 1135 | 0.020 |
Why?
|
| Bleomycin | 1 | 2011 | 493 | 0.020 |
Why?
|
| Neprilysin | 1 | 1993 | 487 | 0.020 |
Why?
|
| Epitopes | 2 | 1989 | 2529 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 1994 | 962 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 3952 | 0.020 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 1990 | 23 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 6547 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 1990 | 372 | 0.020 |
Why?
|
| Vinblastine | 1 | 2011 | 487 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 12562 | 0.020 |
Why?
|
| Herpesvirus 6, Human | 1 | 1990 | 98 | 0.020 |
Why?
|
| Cause of Death | 1 | 2001 | 3721 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2010 | 192 | 0.020 |
Why?
|
| Hematologic Neoplasms | 2 | 1999 | 1907 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 91 | 0.020 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 1991 | 220 | 0.020 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 1990 | 143 | 0.020 |
Why?
|
| Colony-Stimulating Factors | 1 | 1989 | 218 | 0.020 |
Why?
|
| Actins | 1 | 1997 | 2065 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2014 | 1194 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 411 | 0.020 |
Why?
|
| Herpesviridae Infections | 1 | 1990 | 269 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2010 | 474 | 0.020 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 1990 | 217 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2011 | 559 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 1999 | 2812 | 0.020 |
Why?
|
| Lymphocytes | 4 | 1990 | 2614 | 0.020 |
Why?
|
| Carboplatin | 1 | 2011 | 799 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 4651 | 0.020 |
Why?
|
| Eye Neoplasms | 1 | 1990 | 306 | 0.020 |
Why?
|
| Reference Values | 1 | 1995 | 4940 | 0.020 |
Why?
|
| Transfection | 3 | 1991 | 5763 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1990 | 1065 | 0.020 |
Why?
|
| Calcineurin | 1 | 2008 | 235 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 1987 | 6232 | 0.020 |
Why?
|
| Retinoblastoma | 1 | 1990 | 321 | 0.020 |
Why?
|
| Endothelium | 1 | 1990 | 768 | 0.020 |
Why?
|
| Gene Expression Regulation | 3 | 2002 | 11932 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 1997 | 2893 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2016 | 2576 | 0.020 |
Why?
|
| Physical Examination | 1 | 2013 | 1262 | 0.020 |
Why?
|
| Obstetrics | 1 | 1974 | 682 | 0.020 |
Why?
|
| Graft Rejection | 2 | 1991 | 4492 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 2664 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 1364 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 2960 | 0.020 |
Why?
|
| Melphalan | 3 | 1995 | 421 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 2133 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1891 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2017 | 2986 | 0.020 |
Why?
|
| Probability | 1 | 1991 | 2483 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 1989 | 797 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2009 | 1904 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2006 | 351 | 0.020 |
Why?
|
| Piperazines | 1 | 2016 | 2553 | 0.020 |
Why?
|
| Acute Disease | 3 | 1997 | 7245 | 0.020 |
Why?
|
| Transplantation Chimera | 1 | 2008 | 594 | 0.020 |
Why?
|
| Fatigue | 1 | 2012 | 1557 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 12095 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1987 | 564 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 2631 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1985 | 342 | 0.020 |
Why?
|
| Receptors, Immunologic | 2 | 1991 | 1418 | 0.010 |
Why?
|
| Thymus Gland | 1 | 1990 | 1266 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2830 | 0.010 |
Why?
|
| Antigens | 1 | 1990 | 1444 | 0.010 |
Why?
|
| Leukocyte Count | 2 | 2003 | 1609 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 1793 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 17173 | 0.010 |
Why?
|
| Hybridomas | 1 | 1985 | 444 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3112 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1992 | 4625 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1989 | 1441 | 0.010 |
Why?
|
| Anemia | 1 | 2012 | 1517 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 2002 | 305 | 0.010 |
Why?
|
| Chemokine CXCL13 | 1 | 2002 | 62 | 0.010 |
Why?
|
| Receptors, CXCR5 | 1 | 2002 | 88 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 2014 | 12467 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 2004 | 343 | 0.010 |
Why?
|
| Lung Transplantation | 1 | 2011 | 1309 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2002 | 12174 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 2002 | 249 | 0.010 |
Why?
|
| Receptors, Cytokine | 1 | 2002 | 258 | 0.010 |
Why?
|
| Radiography | 1 | 2013 | 6991 | 0.010 |
Why?
|
| Transcription, Genetic | 2 | 1999 | 7609 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2000 | 38 | 0.010 |
Why?
|
| Multigene Family | 2 | 1998 | 1082 | 0.010 |
Why?
|
| NAD+ Nucleosidase | 1 | 2000 | 43 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 2002 | 528 | 0.010 |
Why?
|
| Patient Selection | 1 | 2012 | 4265 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2001 | 420 | 0.010 |
Why?
|
| Liver | 1 | 2016 | 7578 | 0.010 |
Why?
|
| Brain Neoplasms | 2 | 1994 | 9213 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1990 | 1944 | 0.010 |
Why?
|
| Killer Cells, Natural | 2 | 1990 | 2211 | 0.010 |
Why?
|
| Research Design | 1 | 2016 | 6214 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2002 | 877 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2000 | 42683 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2006 | 2360 | 0.010 |
Why?
|
| Antibodies, Heterophile | 1 | 1999 | 128 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1991 | 4413 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1981 | 838 | 0.010 |
Why?
|
| Embryonal Carcinoma Stem Cells | 1 | 1998 | 20 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 1999 | 364 | 0.010 |
Why?
|
| Genomics | 1 | 2014 | 5928 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2003 | 1830 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 498 | 0.010 |
Why?
|
| bcl-Associated Death Protein | 1 | 1998 | 102 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 3836 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 1998 | 282 | 0.010 |
Why?
|
| Cell Count | 1 | 2000 | 1833 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 1998 | 412 | 0.010 |
Why?
|
| Methylation | 1 | 1999 | 1078 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2003 | 2674 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1989 | 1629 | 0.010 |
Why?
|
| Catalysis | 1 | 1997 | 768 | 0.010 |
Why?
|
| Boston | 1 | 2008 | 9377 | 0.010 |
Why?
|
| COS Cells | 1 | 1997 | 1135 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 1731 | 0.010 |
Why?
|
| Arkansas | 1 | 1974 | 59 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15951 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 2231 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1967 | 2819 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1999 | 1498 | 0.010 |
Why?
|
| History, Modern 1601- | 1 | 1974 | 16 | 0.010 |
Why?
|
| Growth Substances | 2 | 1987 | 760 | 0.010 |
Why?
|
| Forecasting | 1 | 2003 | 2945 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2003 | 6346 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 682 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 1999 | 1120 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1994 | 825 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1997 | 13427 | 0.010 |
Why?
|
| Proto-Oncogenes | 1 | 1993 | 322 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 13594 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1991 | 165 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1992 | 421 | 0.010 |
Why?
|
| Cyclosporins | 1 | 1991 | 216 | 0.010 |
Why?
|
| Receptors, Leukocyte-Adhesion | 1 | 1991 | 53 | 0.010 |
Why?
|
| Paraproteins | 1 | 1991 | 38 | 0.010 |
Why?
|
| Heart Arrest | 1 | 1981 | 1515 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1992 | 642 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1991 | 816 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1992 | 1305 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1991 | 526 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1997 | 5033 | 0.010 |
Why?
|
| Hematocrit | 1 | 1991 | 623 | 0.010 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 1990 | 99 | 0.010 |
Why?
|
| Cytogenetics | 1 | 1990 | 198 | 0.010 |
Why?
|
| Magnetics | 1 | 1992 | 599 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1997 | 2395 | 0.010 |
Why?
|
| Predictive Value of Tests | 2 | 1998 | 15471 | 0.010 |
Why?
|
| Biological Factors | 1 | 1990 | 156 | 0.010 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 1989 | 187 | 0.010 |
Why?
|
| Myeloma Proteins | 1 | 1989 | 71 | 0.000 |
Why?
|
| Interleukin-6 | 2 | 1989 | 3232 | 0.000 |
Why?
|
| Histocompatibility Testing | 1 | 1991 | 716 | 0.000 |
Why?
|
| Splenectomy | 1 | 1990 | 392 | 0.000 |
Why?
|
| Cell Aggregation | 1 | 1989 | 238 | 0.000 |
Why?
|
| Kidney Function Tests | 1 | 1991 | 684 | 0.000 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1990 | 242 | 0.000 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1990 | 767 | 0.000 |
Why?
|
| Antigens, CD19 | 1 | 1992 | 446 | 0.000 |
Why?
|
| Cell Line, Transformed | 1 | 1990 | 867 | 0.000 |
Why?
|
| Chimera | 1 | 1990 | 454 | 0.000 |
Why?
|
| Serum Albumin | 1 | 1992 | 677 | 0.000 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1989 | 1057 | 0.000 |
Why?
|
| Hepatitis | 1 | 1990 | 228 | 0.000 |
Why?
|
| Culture Media | 1 | 1990 | 898 | 0.000 |
Why?
|
| Cricetinae | 1 | 1992 | 2423 | 0.000 |
Why?
|
| Heart | 1 | 1981 | 4447 | 0.000 |
Why?
|
| Isoantibodies | 1 | 1992 | 681 | 0.000 |
Why?
|
| Genes, Neoplasm | 1 | 1989 | 371 | 0.000 |
Why?
|
| Herpes Zoster | 1 | 1990 | 252 | 0.000 |
Why?
|
| Plasma Cells | 1 | 1991 | 599 | 0.000 |
Why?
|
| Blood-Brain Barrier | 1 | 1994 | 1036 | 0.000 |
Why?
|
| Stroke Volume | 1 | 1981 | 5622 | 0.000 |
Why?
|
| RNA, Neoplasm | 1 | 1989 | 751 | 0.000 |
Why?
|
| Methods | 1 | 1987 | 1066 | 0.000 |
Why?
|
| Child | 3 | 1993 | 80960 | 0.000 |
Why?
|
| Pulmonary Fibrosis | 1 | 1990 | 506 | 0.000 |
Why?
|
| Cross-Linking Reagents | 1 | 1989 | 692 | 0.000 |
Why?
|
| Lymphocyte Cooperation | 1 | 1986 | 112 | 0.000 |
Why?
|
| Immunoglobulins | 1 | 1989 | 855 | 0.000 |
Why?
|
| Rural Health | 1 | 1967 | 302 | 0.000 |
Why?
|
| Mitogens | 1 | 1986 | 229 | 0.000 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1993 | 3813 | 0.000 |
Why?
|
| Macrophages | 2 | 1994 | 5801 | 0.000 |
Why?
|
| Interphase | 1 | 1985 | 227 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1989 | 1081 | 0.000 |
Why?
|
| Interferon Type I | 1 | 1989 | 569 | 0.000 |
Why?
|
| Carrier Proteins | 1 | 1998 | 4939 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1989 | 4168 | 0.000 |
Why?
|
| Lymphokines | 1 | 1987 | 927 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1985 | 1142 | 0.000 |
Why?
|
| Infection Control | 1 | 1991 | 985 | 0.000 |
Why?
|
| Feasibility Studies | 1 | 1995 | 5323 | 0.000 |
Why?
|
| Phagocytosis | 1 | 1989 | 1530 | 0.000 |
Why?
|
| Liver Diseases | 1 | 1992 | 1305 | 0.000 |
Why?
|
| Disease Susceptibility | 1 | 1990 | 1794 | 0.000 |
Why?
|
| DNA Replication | 1 | 1990 | 1428 | 0.000 |
Why?
|
| Virus Replication | 1 | 1990 | 2458 | 0.000 |
Why?
|
| Genotype | 1 | 1997 | 13048 | 0.000 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1991 | 2574 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 36854 | 0.000 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1989 | 1803 | 0.000 |
Why?
|
| Particle Size | 1 | 1986 | 1652 | 0.000 |
Why?
|
| Immunity, Cellular | 1 | 1987 | 1560 | 0.000 |
Why?
|
| Length of Stay | 1 | 1994 | 6526 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1990 | 3215 | 0.000 |
Why?
|
| Rats | 1 | 1994 | 23786 | 0.000 |
Why?
|
| Logistic Models | 1 | 1992 | 13318 | 0.000 |
Why?
|
| Radionuclide Imaging | 1 | 1981 | 1998 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1991 | 15889 | 0.000 |
Why?
|
| Brain | 1 | 1994 | 27453 | 0.000 |
Why?
|
| United States | 1 | 1974 | 73186 | 0.000 |
Why?
|